ArticlePituitary2016
Diagnosis and management of acromegaly: the patient's perspective.
Article in Pituitary, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 56 citations in OpenAlex.
- Prevalence of clinical signs, symptoms and comorbidities at diagnosis of acromegaly: a systematic review in accordance with PRISMA guidelines.Pituitary · 2023Pooled it
- The prevalence of acromegaly is higher than previously reported: Changes over a three-decade period.Clinical endocrinology · 2022Pooled it
- Beyond biochemical control: factors associated with quality of life in patients with acromegaly.Pituitary · 2026Article
- Disease-related burden and treatment experience in patients with acromegaly: a gender perspective.Journal of endocrinological investigation · 2026Article
- Acromegaly diagnosis.The Journal of clinical endocrinology and metabolism · 2026Review
- Changing understanding of acromegaly epidemiology and early mortality risk.The Journal of clinical endocrinology and metabolism · 2026Review
- Osteometabolic complications in patients with secreting pituitary adenomas: Is there an impact of gender?Pituitary · 2026Review
- Patients With Pituitary Neuroendocrine Tumours Requiring Neurosurgery -Who Is Referring Them?Clinical endocrinology · 2026Article
- Sex-related differences in healthcare utilization and costs among patients with pituitary adenomas.Pituitary · 2026Review
- Diagnostic Delay in Acromegaly Due to Overlapping Features With Polycystic Ovary Syndrome: A Case Report.Cureus · 2025Article
- From Subtle Signs to Severe Sequelae-A Century of Symptomatology and Comorbidities in the Diagnosis of GH-Secreting Pituitary Neuroendocrine Tumors: A Systematic Review.Diagnostics (Basel, Switzerland) · 2025Review
- Knowledge and attitudes of primary care physicians regarding acromegaly: a survey study with multinational participation.BMC primary care · 2024Article
- The changing landscape of acromegaly - an epidemiological perspective.Reviews in endocrine & metabolic disorders · 2024Review
- Consensus on criteria for acromegaly diagnosis and remission.Pituitary · 2024Article
- Carney complex- why thorough medical history taking is so important - report of three cases and review of the literature.Endocrine · 2023Review
- Clinical features and complications of acromegaly at diagnosis are not all the same: data from two large referral centers.Endocrine connections · 2021Article
- Prognostic factors of biochemical remission after transsphenoidal surgery for acromegaly: a structured review.Pituitary · 2020Review
- Gender differences and temporal trends over two decades in acromegaly: a single center study in 112 patients.Endocrine · 2020Article
- Patient Characteristics, Diagnostic Delays, Treatment Patterns, Treatment Outcomes, Comorbidities, and Treatment Costs of Acromegaly in China: A Nationwide Study.Frontiers in endocrinology · 2020Article
- Neuromuscular Blockade Correlates with Hormones and Body Composition in Acromegaly.International journal of endocrinology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeEarly diagnosis is a success factor for the prevention of long-term comorbidity and premature death in patients with acromegaly, but large-scale data on the diagnostic process and disease management are scarce. Therefore, we aimed to evaluate the diagnostic process, implementation of treatment and changes in life situation in patients with acromegaly, focusing on sex-specific differences.
methodsNon-interventional patient-reported outcome study. 165 patients with clinically and biochemically proven acromegaly were questioned about the diagnostic process and utilization of health care by means of a self-developed standardized postal survey including questions on acromegaly symptoms experienced before diagnosis, number and specialty of consulted doctors, time to diagnosis and aftercare.
resultsThe diagnostic process took 2.9 (SD 4.53) years, during which 3.4 (SD 2.99) physicians were consulted. Women waited longer [4.1 (SD 5.53) years] than men [1.6 (SD 2.69) years; p = 0.001] for the correct diagnosis, and consulted more doctors in the process [4.0 (SD 2.99) vs. 2.7 (SD 2.84) doctors, p < 0.001, respectively]. In 48.5 % of patients, acromegaly was diagnosed by an endocrinologist (men: 45.1 %; women: 52.4 %). Overall disease duration from symptom onset until last surgery was 5.5 (SD 6.85) years, with no sex differences. A change in employment status was the most commonly reported event after diagnosis and a quarter of the patients stated that the illness had changed their lives.
conclusionsOur findings confirm the urgent need to increase awareness of the clinical manifestation of acromegaly to facilitate an earlier diagnosis of the disease and to provide diagnostic equality across the sexes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.